Richard Pasternak, a veteran academic and scientist, has become chairman of Cerenis Therapeutics SA of France, succeeding Jean-Pierre Garnier. Dr Pasternak has been a non-executive director of the company, which is developing treatments for cardiovascular disease, since 2011. He is also a professor at the Weill Cornell Medical College in New York City and an advisor to the healthcare venture firm Bay City Capital. Previously Dr Pasternak was head of global scientific affairs at Merck & Co Inc and director of preventive cardiology and cardiac rehabilitation at the Massachusetts General Hospital in Boston.
Cerenis announced the appointment on 3 September 2014.
Copyright 2014 Evernow Publishing Ltd